Clinical Trial

Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients

Study acronym: RASROP-003
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-06.
Trial Details
NCT Number NCT07465458
Lead Sponsor Humanitas Hospital, Italy
Collaborators: SACMI-Sociedad Aragonesa de Cirugìa Minimamante Invasiva
Conditions Renal Carcinoma
Enrollment 226 participants
Start Date 2026-03
Primary Completion 2028-03 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-16